EGM
RLMD icon

Engineers Gate Manager’s Relmada Therapeutics RLMD Stock Holding History

Engineers Gate Manager’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-13,687
Closed -$63.6K – 2184
2024
Q1 		$63.6K Buy
+13,687
New +$66K ﹤0.01% 1789
2023
Q1 		– Sell
-45,424
Closed -$159K – 1947
2022
Q4 		$159K Buy
+45,424
New +$399K 0.01% 1427

Other funds holding RLMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Engineers Gate Manager's RLMD Position: Q2 2024 in Review

Engineers Gate Manager sold out of Relmada Therapeutics (RLMD) in Q2 2024, closing a stake of 13,687 shares — an estimated $63.6K sold.

Engineers Gate Manager first reported a position in RLMD in Q4 2022 and held it in 2 quarters. The position peaked at $159K in Q4 2022. 79 funds tracked by Wall St. Rank hold RLMD as of Q2 2024.

  • Engineers Gate Manager reported no remaining Relmada Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Engineers Gate Manager sold 13,687 Relmada Therapeutics shares in Q2 2024, an estimated $63.6K.
  • Engineers Gate Manager first reported a position in Relmada Therapeutics in Q4 2022 and held it in 2 quarters.
  • Engineers Gate Manager's Relmada Therapeutics position peaked at $159K in Q4 2022.
  • 79 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2024.

Based on Engineers Gate Manager's 13F filing for Q2 2024, filed 14 Aug 2024.